Top 1% Biotech Viking Therapeutics Backs Off Its Record Run On NASH Enthusiasm

unveiled promising test results Tuesday for a liver disease treatment, but VKTX stock reversed from premarket gains and sank at the open. The company is working on a treatment for nonalcoholic steatohepatitis, or NASH. With NASH, patients experience inflammation and damage in the liver unrelated…#nash #insightpartners #vk2809 #brianlian #marketsmithcom #ibddigital #elililly #trackandbuy
Source: Reuters: Health - Category: Consumer Health News Source Type: news